Dow Chemical: Analysts' Upgrades, Downgrades - TheStreet

Dow Chemical: Analysts' Upgrades, Downgrades

Dow Chemical upgraded at Deutsche Bank from Hold to Buy.
Author:
Publish date:

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Abercrombie & Fitch

(ANF) - Get Report

upgraded at Brean Murray from Sell to Hold. $33 price target. Stock is already pricing in lower sales and slower international growth.

Dow Chemical

(DOW) - Get Report

upgraded at Deutsche Bank from Hold to Buy. Coverage was reinstated and cost synergies from a recent acquisition are running ahead of plan. $32 price target.

First Solar

(FLSR)

rated new Buy at Goldman. $150 price target. Company should begin to see larger US installations.

Hanesbrands

(HBI) - Get Report

initiated at Barclays with an Overweight rating and $35 price target. Hanesbrands switching from a "build it" investment story to a "leverage it" growth story, Barclays said.

Live Nation

(LVY)

upgraded at Morgan Joseph from Hold to Buy. $14 price target. Next year should be strong for major concert tours.

Quadra FNX

(QUX)

upgraded at BofA/Merrill to Buy from Neutral. Valuation call.

MEMC Electronic

(WFR)

rated new Sell at Goldman. $9 price target. Company has higher capital needs and runs at relatively low margins.

Williams-Sonoma

(WSM) - Get Report

upgraded at Wells from Market Perform to Outperform. Checks show that the business is seeing positive momentum.

STOCK COMMENTS / EPS CHANGES

Becton Dickinson

(BDX) - Get Report

numbers cut at Goldman. Shares of BDX now seen reaching $66. Estimates also lowered, following the division sale. Sell rating.

Bucyrus

(BUCY)

estimates, target cut at Morgan Stanley. Shares of BUCY now seen reaching $77. Estimates also lowered, given the loss of a contract in India. Overweight rating.

Coach

(COH)

estimates increased at Goldman through 2012. New analyst sees further growth potential in China and Europe. Neutral rating and $43 price target.

Computer Sciences

(CSC)

target lowered at Kaufman to $53. Company could be hurt by lower government spending. Hold rating.

Gap

(GPS) - Get Report

target lowered at UBS to $22. Promotion levels have been increasing in retail. Neutral rating.

Hospira

(HSP)

estimates, target boosted at Goldman. Shares of HSP now seen reaching $70. Estimates also upped, as the company should gain business from BAX's infusion pump recall. Buy rating.

Johnson & Johnson

(JNJ) - Get Report

numbers lowered at Goldman through 2012. European budget concerns and the consumer recall will weigh on earnings. Neutral rating and new $64 price target.

KB Home

(KBH) - Get Report

estimates, target cut at JMP. Shares of KBH now seen reaching $17. Estimates also lowered, lower expected deliveries and margins. Outperform rating.

KB Home

(KBH) - Get Report

price target lower at Barclays to $15. More cautious on KBH's second half. Equal weight rating.

Lowe's

(LOW) - Get Report

price target cut at Credit Suisse to $27 from $31on expectations of a weak second half of 2010. Maintain Outperform rating.

Medco Health

(MHS)

added to Conviction Buy List at Goldman. Domestic defensive plays should continue to outperform in healthcare.

Micron

(MU) - Get Report

estimates upped at JMP through 2011. Pricing was likely healthy during the quarter, even though it may have plateaued. Outperform rating.

Office Depot

(ODP) - Get Report

price target lower at BofA/Merrill to $4 from $7 to reflect still-challenging fundamentals. Maintain Underperform rating.

Pfizer

(PFE) - Get Report

cut from Conviction List at Goldman. Management will likely have to return more cash to shareholders to help unlock value in the stock.

St. Jude

(STJ)

estimates, target upped at Goldman through 2013. Higher ICD sales should offset currency concerns. Neutral rating and new $43 price target.

Triumph

(TGI) - Get Report

estimates, target raised at Oppenheimer. Shares of TGI now seen reaching $90. Estimates also increased, given the recent acquisition of Vought. Outperform rating.

Exxon Mobil

(XOM) - Get Report

numbers reduced at Goldman through 2013. XTO deal will dilute earnings. Neutral rating and new $65 price target.

This article was written by a staff member of TheStreet.com.